Categories
Latest Industry Intelligence
Dr. Tom Knapman, Director of Strategic Brand at SCIEX, explains how bioconvergent advances will help [...]
The Lab of the Future will fuse automation, speed and remote work says Thomas Marshall, [...]
Pfizer is to acquire commercial-stage biopharmaceutical company Biohaven in a deal worth $11.6 billion. Biohaven is developing therapies for the treatment of migraine. The company’s lead product NURTEC ODT is a dual-acting migraine therapy which has been approved in the US for adult patients. The therapy has also been approved in the EU for both […]